STOCK TITAN

Nephros holder Wexford now reports 2.06% stake

Wexford Capital and affiliates cut their NEPH stake to 2.06% and report falling below the 5% beneficial-ownership threshold on September 14, 2026.

(Moderate)
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Nephros, Inc. (NEPH) is the subject of an Amendment No. 12 to a Schedule 13D filed by Wexford Capital LP and affiliated reporting persons. They now report beneficial ownership of 223,539 shares of common stock, representing 2.06% of Nephros’s outstanding shares as of August 7, 2026.

On September 14, 2026, Wexford Capital effected an in-kind distribution of certain Nephros shares from affiliated funds and vehicles to their underlying investors and sold additional shares to an entity controlled by Nephros director Arthur Amron, with proceeds distributed to underlying investors. The reporting persons state they ceased to be beneficial owners of more than five percent of Nephros common stock on that date.

Positive

  • None.

Negative

  • None.

Filing Explained

The completed transfer changed holder ownership records while leaving Wexford with 223,539 shares and shared voting and dispositive power.

The September 14, 2026 transfer is complete; the filing leaves Wexford-related reporting persons below 5% while retaining shared voting and dispositive power over 223,539 shares, or 2.06%.

The disclosed movement was between Wexford-related entities, their underlying investors, and an entity controlled by director Arthur Amron, so it changes holder ownership rather than describing a new company issuance or capital proceeds to Nephros.

The in-kind distribution involved no purchase, sale, or additional consideration. The separate sale transferred shares to the Amron-controlled entity, with proceeds distributed to certain underlying investors; the distributing entities were to receive no compensation.

Beneficially owned shares 223,539 shares Common stock of Nephros reported by each Wexford reporting person
Percent of class beneficially owned 2.06% Portion of Nephros common stock beneficially owned by the reporting persons
Shares outstanding 10,860,120 shares Nephros common stock issued and outstanding as of August 7, 2026, used for ownership calculation
Date reporting persons fell below 5% ownership September 14, 2026 Date they ceased to be beneficial owners of more than five percent of Nephros common stock
Amendment number Amendment No. 12 Amendment to the existing Schedule 13D on Nephros common stock
in-kind distribution financial
"effected (i) an in-kind distribution of certain shares of common stock"
A distribution of value to shareholders or beneficiaries made by transferring assets instead of paying cash, such as shares, bonds, or property. Like receiving a box of goods rather than money, it changes what you hold rather than adding liquid funds; investors care because it affects a portfolio’s composition, liquidity, tax reporting, and cost basis for the received assets.
beneficially owned financial
"for the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
pecuniary interests financial
"except, in the case of Davidson and Jacobs, to the extent of their respective pecuniary interests therein"
dispositive power financial
"power to vote and to dispose of the shares of Common Stock"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
Schedule 13D regulatory
"initially filed the Statement on Schedule 13D"
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in NEPH does Wexford Capital now report in this Schedule 13D/A?

Wexford Capital and affiliated reporting persons report beneficial ownership of 223,539 shares of Nephros common stock, representing 2.06% of the outstanding shares, based on 10,860,120 shares outstanding as of August 7, 2026.

When did Wexford Capital fall below 5% ownership of NEPH common stock?

The reporting persons state they ceased to be the beneficial owner of more than five percent of Nephros common stock on September 14, 2026.

What transactions did Wexford Capital report involving NEPH on September 14, 2026?

On September 14, 2026, Wexford Capital reported (i) an in-kind distribution of certain Nephros shares from three affiliated entities to their underlying investors, and (ii) a sale of certain shares to an entity controlled by director Arthur Amron, with proceeds distributed to certain underlying investors.

Did the distributing entities receive compensation in the reported NEPH transactions?

The filing states that no distributing entities shall receive any compensation, directly or indirectly, in connection with the in-kind distribution and the sale of Nephros shares described in the amendment.

How many NEPH shares were outstanding for the ownership calculation in this filing?

The 2.06% ownership figure is calculated using 10,860,120 shares of Nephros common stock issued and outstanding as of August 7, 2026, as reported by Nephros in its Form 10-Q filed on August 10, 2026.

Who are the reporting persons in the NEPH Schedule 13D/A Amendment No. 12?

The reporting persons are Wexford Capital LP, Wexford GP LLC, Charles E. Davidson, and Joseph M. Jacobs, who may be deemed to share voting and dispositive power over the Nephros shares held by specified Wexford-related entities, subject to stated disclaimers of beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





640671400

(CUSIP Number)
Mark Ahern
c/o Wexford Capital LP,, 777 South Flagler Drive, Suite 602 East
West Palm Beach, FL, 33401
561-273-8588

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
09/14/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Wexford Capital LP
Signature:/s/ Mark E. Ahern
Name/Title:By: Wexford GP LLC, its General Partner, By: Mark E. Ahern, Vice President and Assistant Secretary
Date:09/16/2026
Wexford GP LLC
Signature:/s/ Mark E. Ahern
Name/Title:Mark E. Ahern, Vice President and Assistant Secretary
Date:09/16/2026
Charles E. Davidson
Signature:/s/ Charles E. Davidson
Name/Title:Charles E. Davidson
Date:09/16/2026
Joseph M. Jacobs
Signature:/s/ Joseph M. Jacobs
Name/Title:Joseph M. Jacobs
Date:09/16/2026

Keep reading